Skip to main content
    S

    Sutro Biopharma (STRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.52
    -0.49 (-4.45%)

    Market Cap: $174.43M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(16/32)
    Avg Surprise
    -133.74%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.07
    Range$-2.38 - $-1.45
    3 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.37+12.7%
    60d ago$-2.53+18.3%
    30d ago$-2.53+18.3%
    7d ago$-2.53+18.3%
    Current$-2.07
    Revenue Consensus
    $14M
    Range$3M - $50M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.20
    Range$-2.75 - $1.19
    3 analysts
    Revenue Consensus
    $19M
    Range$-2703820 - $92M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-2.07---
    Jun 26
    Reported Aug 12
    		$-2.33$-2.04-14.22%Miss-1564.3%
    Mar 26
    Reported May 14
    		$-2.94$-3.21+8.41%Beat+63.3%
    Dec 25
    Reported Mar 23
    		$-5.45$-0.43-1152.85%Miss-760.3%
    Sep 25
    Reported Nov 6
    		$-5.57$-3.55-56.90%Miss-11.8%
    Jun 25
    Reported Aug 7
    		$-0.14N/A+64.10%Beat+97.5%
    Mar 25
    Reported May 8
    		$-8.02$-9.20+12.83%Beat+9.9%
    Dec 24
    Reported Mar 13
    		$-0.63$-0.95+33.70%Beat-221.8%
    Sep 24
    Reported Nov 13
    		$-4.98$-7.35+32.24%Beat+38.5%
    Jun 24
    Reported Aug 13
    		$-5.61$-9.00+37.67%Beat+27.0%
    Mar 24
    Reported May 13
    		$-8.90$-9.95+10.55%Beat-947.1%
    Dec 23
    Reported Mar 25
    		$0.52$-0.82+163.41%Beat+106.4%
    Sep 23
    Reported Nov 13
    		$-8.10$-7.15-13.29%Miss-118.9%
    Jun 23
    Reported Aug 10
    		$-7.69$-6.87-11.94%Miss-39.8%
    Mar 23
    Reported May 15
    		$-0.85$-0.81-4.94%Miss+89.9%
    Dec 22
    Reported Mar 30
    		$-8.18$-6.32-29.43%Miss-885.5%
    Sep 22
    Reported Nov 8
    		$-3.70$0.12-3183.33%Miss+44.8%
    Jun 22
    Reported Aug 8
    		$-5.50$-7.70+28.57%Beat-323.1%
    Mar 22
    Reported May 9
    		$-8.40$-7.37-13.98%Miss-96.3%
    Dec 21
    Reported Feb 28
    		$-0.83$-0.69-20.29%Miss+43.9%
    Sep 21
    Reported Nov 10
    		$-6.70$-4.80-39.58%Miss-100.6%
    Jun 21
    Reported Aug 9
    		$-1.30N/A+67.50%Beat+78.2%
    Mar 21
    Reported May 7
    		$-4.28$-6.00+28.67%Beat+49.0%
    Dec 20
    Reported Mar 18
    		$-1.48$-0.57-159.65%Miss-131.3%
    Sep 20
    Reported Nov 5
    		$-3.34$-5.00+33.20%Beat+40.4%
    Jun 20
    Reported Aug 6
    		$-5.97$-5.74-4.01%Miss+0.5%
    Mar 20
    Reported May 11
    		$-8.40$-5.68-47.89%Miss-35.5%
    Dec 19
    Reported Mar 16
    		$-0.64$-0.69+7.25%Beat-146.2%
    Sep 19
    Reported Nov 8
    		$-5.60$-6.17+9.24%Beat-29.0%
    Jun 19
    Reported Aug 14
    		$-6.00$-6.01+0.17%Beat-338.0%
    Mar 19
    Reported Apr 1
    		$-6.20$-6.10-1.64%Miss-
    Dec 18
    Reported Dec 31
    		$-0.26N/A+58.73%Beat-
    Sep 18
    Reported Nov 14
    		$-4.34N/A-122.03%Miss-
    Jun 18
    Reported Sep 26
    		$-1.37$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.65EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-301.70%
    ROE-1810.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-3.51x
    Current Ratio3.32xQuick Ratio3.32x
    Trading Statistics
    Beta1.50Avg Volume343.23K
    52-Week High$43.8552-Week Low$7.15

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.00
    SMA 20$14.95
    SMA 50$18.48
    SMA 200$23.11
    EMA 10$13.50
    EMA 20$14.88
    EMA 50$18.04
    EMA 200$20.70

    MACD

    Line: -1.76Signal: -1.48Hist: -0.28

    ADX

    ADX: 56.5+DI: 6.3-DI: 37.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$15.32

    Bollinger Bands

    Upper Band$18.19
    Lower Band$11.70
    %B Position4340%(Upper)
    Band Width-0.18

    RSI (14-Day)

    Oversold
    17.6

    Momentum Oscillators

    Stoch %K5.8
    Stoch %D12.5
    Williams %R-97.5
    ROC (10d)-34.7%
    Momentum-5.59
    CCI (20d)-284.3
    MFI (14d)43.0

    Volatility Measures

    ATR (14d)$1.31(12.4%)
    StdDev (20d)1.62
    Hist Vol77.8%(High)

    Volume Flow

    VWAP$10.73
    OBV458.2K
    AD Line29.2B
    CMF (20d)-0.099

    Volume Metrics

    Avg Vol (20d)299.2K
    Vol Ratio1.6x(High)
    VWMA (20d)$14.69

    Pivot Points

    R3$14.86
    R2$14.02
    R1$12.52
    Pivot Point$11.68
    S1$10.17
    S2$9.33
    S3$7.83

    Advanced Oscillators

    TSI-50.50
    Ultimate Osc31.1
    KST-233.36

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.84M$14.52M$11.65M$9.69M$63.74M$17.40M$14.81M$8.52M$25.71M$13.01M$113.72M$16.92M
    Cost of Revenue$0$0$1.62M$0$0$0$-1,738,000$0$0$0$1.73M$0
    Gross Profit$9.84M$14.52M$11.65M$9.69M$63.74M$17.40M$14.81M$8.52M$25.71M$13.01M$113.72M$16.92M
    Operating Expenses$39.73M$44.18M$49.70M$58.15M$67.09M$85.91M$80.07M$76.44M$74.39M$69.60M$70.57M$60.94M
    R&D$31.70M$36.55M$36.64M$39.85M$38.33M$51.60M$71.04M$62.11M$62.02M$56.88M$53.77M$45.67M
    SG&A$7.83M$7.58M$8.66M$8.74M$10.34M$13.27M$9.03M$14.33M$12.37M$12.72M$16.80M$15.27M
    Operating Income$-29,888,000$-29,656,000$-38,049,000$-48,459,000$-3,345,000$-68,514,000$-65,258,000$-67,919,000$-48,685,000$-56,591,000$43.15M$-44,014,000
    Interest Income$1.72M$1.64M$1.53M$2.01M$2.52M$3.19M$4.76M$4.88M$4.91M$4.10M$4.56M$4.55M
    Interest Expense$10.37M$10.48M$10.32M$10.41M$10.69M$10.64M$1.10M$-14,257,000$9.04M$9.40M$8.73M$8.68M
    Income Before Tax$-38,532,000$-38,499,000$-46,837,000$-56,857,000$-11,517,000$-75,961,000$-70,088,000$-48,787,000$-48,010,000$-58,213,000$46.87M$-47,445,000
    Income Tax Expense$1,000$-15,000$0$0$-18,000$7,000$0$0$8,000$0$15.81M$1.84M
    Net Income$-38,533,000$-38,484,000$-46,762,000$-56,857,000$-11,499,000$-75,968,000$-72,443,000$-48,787,000$-48,018,000$-58,213,000$31.07M$-49,284,000
    EBITDA$-29,079,000$-28,823,000$-36,956,000$-47,314,000$-2,478,000$-67,730,000$-64,929,000$-68,817,000$-44,914,000$-53,807,000$49.72M$-43,975,000
    EBIT$-29,888,000$-29,656,000$-38,049,000$-48,459,000$-3,345,000$-68,514,000$-65,258,000$-67,919,000$-43,877,000$-52,912,000$51.05M$-43,320,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about STRO

    News

    STRO Reiterated by Wedbush -- Price Target Maintained at $60

    Wedbush has reiterated an Outperform rating for Sutro Biopharma (STRO), maintaining a price target of $60.00, despite the stock currently trading significantly above its GF Value™ of $4.89. The company's GF Score™...

    GuruFocus•10/15/26•Neutral

    Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

    Sutro Biopharma, Inc. (NASDAQ: STRO) announced its participation in the 17th Annual World ADC Conference, where it will present on significant progress across its pipeline. Presentations will cover the early clinical...

    Yahoo! Finance Canada•10/12/26•Somewhat-Bullish

    Sutro Biopharma Inc (STRO-Q) Stock Price and News

    This page provides stock price and news information for Sutro Biopharma Inc. (STRO-Q), including real-time quotes, historical data, and analyst ratings. The company develops and manufactures pharmaceutical products...

    The Globe and Mail•10/3/26•Neutral

    An oncology dealmaker with partnerships worth over $2 billion joins Sutro

    Sutro Biopharma (STRO) has appointed Lucas Donigian as Senior Vice President of Business Development, effective September 28, 2026. Donigian brings over 20 years of biotechnology experience...

    Stock Titan•9/30/26•Neutral

    Form 4 Sutro Biopharma For: 27 September By Investing.com

    This article from Investing.com announces the filing of Form 4 for Sutro Biopharma on September 27. It includes a brief mention of the company's stock symbol (STRO) and its percentage change. The content primarily...

    Investing.com India•9/27/26•Neutral

    STRO Valuation and Fair Value

    P/E
    -0.6x
    Forward P/E
    10.0x
    P/B
    -1.7x
    See GNG's fair value

    STRO Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -301.7%
    Net margin
    0.0%
    ROE
    -1810.0%
    FCF margin
    -318.6%

    STRO Competitors

    CompanyTicker
    Invivyd Inc.IVVD
    Oramed Pharmaceuticals IncORMP
    Sionna Therapeutics, Inc. Common StockSION
    Whitehawk Therapeutics, Inc.WHWK
    Sharps Technology IncSTSS
    Precision BioSciences IncDTIL
    Upstream Bio, Inc.UPB
    Coherus BioSciences IncCHRS

    Sector: Healthcare

    STRO Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    3
    Buy
    10
    Hold
    0
    Sell
    0
    Strong Sell
    1

    STRO Bull Case vs Bear Case

    Bull case

    • 92.9% of STRO's analyst ratings are Buy or Strong Buy.

    Bear case

    • STRO's quarterly revenue changed -84.6% year over year.

    STRO Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -134.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About STRO

    Does STRO pay dividends?

    Sutro Biopharma (STRO) does not currently pay a regular dividend.

    What is STRO's market cap?

    Sutro Biopharma (STRO) has a market capitalization of $174.43M with a current stock price of $10.52.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In